Neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains
Authors:
Open Access
- 1 January 2014
- journal article
- research article
- Published by Japanese Society of Toxicology in The Journal of Toxicological Sciences
- Vol. 39 (2) , 251-262
Abstract
The neuroprotective effects of dexmedetomidine have been reported by many investigators; however its underlying mechanism to reduce neuronal injury during a prolonged anesthesia remains unclear. In this study, we investigated the neurotoxic effects of dexmedetomidine in fetal monkey brains. In the present study, we compare the neurotoxic effects of dexmedetomidine and ketamine, a general anesthetic with a different mechanism of action, in fetal cynomolgus monkeys. Twenty pregnant monkeys at approximate gestation day 120 were divided into 4 groups: non-treatment controls (Group 1); ketamine at 20 mg/kg intramuscularly followed by a 12-hr infusion at 20-50 mg/kg/hr (Group 2); dexmedetomidine at 3 µg/kg intravenously (i.v.) over 10 min followed by a 12-hr infusion at the human equivalent dose (HED) of 3 µg/kg/hr (Group 3); and dexmedetomidine at 30 µg/kg i.v. over 10 min followed by a 12-hr infusion at 30 µg/kg/hr, 10 times HED (Group 4). Blood samples from both dams and fetuses were measured for concentration of dexmedetomidine. Each fetus was perfusion-fixed, serial sections were cut through the frontal cortex, and stained to detect for apoptosis (activated caspase 3 and TUNEL) and neurodegeneration (silver stain). In utero treatment with ketamine resulted in marked apoptosis and degeneration primarily in layers I and II of the frontal cortex. In contrast, fetal brains from animals treated with dexmedetomidine showed none to minimal neuroapoptotic or neurodegenerative lesions at both low- and high-dose treatments. Plasma levels confirmed systemic exposure of dexmedetomidine in both dams and fetuses. In conclusion, these results demonstrate that dexmedetomidine at both low-dose (HED) and high-dose (10 times HED) does not induce apoptosis in the frontal cortex (layers I, II, and III) of developing brain of cynomolgus monkeys.Keywords
This publication has 29 references indexed in Scilit:
- GABAA receptor antagonism increases NMDA receptor inhibition by isoflurane at a minimum alveolar concentrationVeterinary Anaesthesia and Analgesia, 2011
- Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeysNeurotoxicology and Teratology, 2011
- GABAA positive modulator and NMDA antagonist-like discriminative stimulus effects of isoflurane vapor in micePsychopharmacology, 2010
- Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic‐induced neuroapoptosis in the rat developing brainActa Anaesthesiologica Scandinavica, 2010
- Isoflurane-induced Neuroapoptosis in the Neonatal Rhesus Macaque BrainAnesthesiology, 2010
- Xenon Mitigates Isoflurane-induced Neuronal Apoptosis in the Developing Rodent BrainAnesthesiology, 2007
- Arrestin Serves as a Molecular Switch, Linking Endogenous α2-Adrenergic Receptor to SRC-dependent, but Not SRC-independent, ERK ActivationJournal of Biological Chemistry, 2006
- Simultaneous quantitation of dexmedetomidine and glucuronide metabolites (G‐Dex‐1 and G‐Dex‐2) in human plasma utilizing liquid chromatography with tandem mass spectrometric detectionRapid Communications in Mass Spectrometry, 2004
- The Effect of the α2-Agonist Dexmedetomidine and the N-Methyl-d-Aspartate Antagonist S(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins After Incomplete Cerebral Ischemia and Reperfusion in RatsAnesthesia & Analgesia, 2003
- Transfer of clonidine and dexmedetomidine across the isolated perfused human placentaActa Anaesthesiologica Scandinavica, 1997